Effects of Chelation Therapy on Cardiac Function Improvement in Thalassemia Patients: Literature Review and the Taiwanese Experience

REFERENCES

• Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with β-thalassemia major. Ann Hematol 2004; 83(12)779–783
   PubMedGoogle Scholar
• Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23(5)662–668
   PubMed Web of Science ®Google Scholar
• Aessopos A, Deftereos S, Tsironi M, Karabatsos F, Yousef J, Fragodimitri C, Hatziliami A, Karagiorga M. Predictive echo-Doppler indices of left ventricular impairment in β-thalassemic patient. Ann Hematol 2007; 86(6)429–434
   PubMedGoogle Scholar
• Roberts EB, Schafer F, Akhfur W, Patel D, Evans TR, Coghlan JG, Lipkin DP, Davar JI. Real-time myocardial contrast dobutamine stress echocardiography in coronary stenosis. Int J Cardiol 2006; 113(1)19–24
   PubMedGoogle Scholar
• Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from deferoxamine to deferiprone in β-thalassemia major patients. Hemoglobin 2006; 30(2)229–238
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassemia major. Lancet 1989; 2(8653)27–30
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220)2051–2052
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineous E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5)359–366
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Pippard MJ, Callender ST. Iron loading in thalassemia: five years with the pump. N Engl J Med 1983; 308(8)456–458
   PubMedGoogle Scholar
• Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332(14)918–922
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): 1, iron chelation and metabolic studies. Br J Haematol 1990; 76(2)295–300
   PubMed Web of Science ®Google Scholar
• Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82(2)460–466
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339(7)417–423
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients. Blood 1998; 91(1)295–300
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520
   PubMed Web of Science ®Google Scholar
• Piga A, Gagliotic C, Fogliacco E, Tricta F. Comparative effects of deferioprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88(5)489–496
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9)3738–3744
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107(9)3733–3737
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23)2171–2179
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Hematologica 2004; 89(10)1187–1193
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95(1)26–36
   PubMed Web of Science ®Google Scholar
• Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol 2000; 110(4)971–977
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, Wayne AD, Martin M, McGee A, Koren G, Liu PP, Cohen AR. Survival of medically treated patients with homogygous β thalassemia. N Engl J Med 1994; 331(9)574–578
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9)567–573
   PubMed Web of Science ®Google Scholar
• Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous β-thalassaemia and transfusional iron overload. Br J Haematol 1980; 46(3)409–416
   PubMedGoogle Scholar
• Kolnagou A, Economides C, Eracleous E, Kontoghioghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2)219–227
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka M, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103(5)1934–1936
   PubMed Web of Science ®Google Scholar
• Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6)392–397
   PubMed Web of Science ®Google Scholar
• Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regress severe heart failure in patients with β-thalassemia major. Ann Hematol 2004; 83(7)471–473
   PubMed Web of Science ®Google Scholar
• Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92(1)131–132
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Warner GT, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassaemia intermedia. Lancet 1979; 2(8147)819–821
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5)327–331
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14–34
   PubMedGoogle Scholar
• Desferal R. Product Monograph. Novartis Inc, BaselSwitzerland 1998
   Google Scholar
• Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, refractory anemia with hemochromatosis. Circulation 1964; 30(5)698–705
   PubMedGoogle Scholar
• Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104(1)263–269
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3)348–355
   PubMed Web of Science ®Google Scholar
• Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with β-thalassemia major. Hemoglobin 2006; 30(2)251–256
   PubMed Web of Science ®Google Scholar
• Peng CT, Wu KH, Wu SF, Liang DC, Yang CP, Jang RC, Wang LY, Hsiao CC. Deferiprone or deferoxamine versus combination therapy in patients with β-thalassemia major: a case study in Taiwan. Hemoglobin 2006; 30(1)125–130
   PubMed Web of Science ®Google Scholar
• Abstract Book: 15th International Conference on Oral Chelation in The Treatment of Thalassemia and Other Diseases. April, 22–262005. Taichung, Taiwan
   Google Scholar
• Grady RW, Berdoukas V, Rachmilewitz EA. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. Blood 2002; 100(Suppl 1)241
   Google Scholar
• Olivieri NF. The β-thalassemias. N Engl J Med 1999; 341(2)99–109
   PubMed Web of Science ®Google Scholar
• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99(1)36–43
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97(11)3411–3416
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9)886–895
   PubMed Web of Science ®Google Scholar
• Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995; 86(5)2008–2013
   PubMedGoogle Scholar